Olivier Brandicourt, physician and head of French pharmaceutical company Sanofi, was born February 13, 1956 in Casablanca.
Olivier Brandicourt initially studied biology at the University Paris VII and then specialized in tropical medicine at the University Paris Descartes.
Olivier Brandicourt, French physician and biologist, age 60, has 28 years of experience in the pharmaceutical industry. During his career, he has forged an international profile through work in many European countries, the United States and Canada.
A doctor by training, he spent eight years in the service of Infectious and Tropical Diseases at the celebrated teaching hospital, Pitié Salpêtrière Hospital, in Paris. During his research, he specialized in malaria in Central Africa and elsewhere while working for two years as a doctor in the Republic of Congo.
Brandicourt then began his industrial career as medical director for Africa for Parke-Davis, which later merged with Warner-Lambert as medical director. He was given the task of developing an anti-malarial drug.
After the giant U.S. pharmaceutical company Pfizer acquired the company in 2000, Brandicourt became director of a larger group focusing on general medicine.
During his time at Pfizer, he led its Global Primary Care unit, its Global Specialty Care business unit and its cardiology business in the United States.
In 2013, he joined Bayer HealthCare group as CEO of the Health Section and member of the executive committee of the section.
In April 2015, he became CEO of Sanofi, France’s leading pharmaceutical company and second largest in the world with 110,000 employees.
Brandicourt is a member of the board of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), and member of the international committee of the Board of the Pharmaceutical Research Manufacturers of America (PhRMA).
Brandicourt received a signing bonus of 4 million euros when he joined Sanofi, an amount that drew criticism from some unions and members of the French government. The company said the bonus offset benefits he lost by leaving Bayer HealthCare.